Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in highrisk populations, Spain, 2016
Martínez Gómez, Xavier (Hospital Universitari Vall d'Hebron)
Curran, Adrian (Hospital Universitari Vall d'Hebron)
Campins Martí, Magda (Hospital Universitari Vall d'Hebron)
Alemany, Laia (Institut Català d'Oncologia)
Rodrigo-Pendás, José Ángel (Hospital Universitari Vall d'Hebron)
Borruel, Natalia (Hospital Universitari Vall d'Hebron)
Castellsagué, Xavier (Institut Català d'Oncologia)
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron)
Moraga-Llop, F. A. (Asociación Española de Vacunología)
del Pino, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Torné, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Universitat Autònoma de Barcelona

Date:	2019
Abstract:	Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. Aim: To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. Methods: We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results: A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9-26 years; men who have sex with men aged 9-26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9-26 years; and patients diagnosed with recurrent respiratory papillomatosis. Conclusions: Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence- based guidelines on HPV vaccination in highrisk populations in Spain, based on best available scientific evidence.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; Article ; Versió publicada
Subject:	Evidence-based medicine ; Human papillomavirus infection ; HPV ; Vaccines ; Immunisation ; High-risk populations ; HIV infection ; HIV ; Men who have sex with men ; MSM
Published in:	Eurosurveillance, Vol. 24 Núm. 7 (14 2019) , p. 1700857, ISSN 1560-7917

DOI: 10.2807/1560-7917.ES.2019.24.7.1700857
PMID: 30782268

14 p, 278.2 KB

The record appears in these collections:
Articles > Published articles